Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
Abstract
:1. Introduction
2. Results
2.1. Study Selection
2.2. General Information about CC-PDX Models
2.3. Quality Assessment
2.4. Treatment of Specimens
2.5. Mouse Strain
2.6. Site of Transplantation
2.7. Engraftment Rate of Each Study
2.8. Comparison of the Original Tumor and PDX
3. Discussion
3.1. Treatment of Specimens
3.2. Mouse Strains
3.3. Site of Transplantation
3.4. PDX Procedure and Success Rate
3.5. Translational Applications of PDX Models
4. Materials and Methods
4.1. Protocol and Registration
4.2. Information Sources and Search Strategies
4.3. Eligibility Criteria
4.4. Study Selection
4.5. Data Extraction and Synthesis
4.6. Quality Assessment
5. Limitation
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Galliverti, G.; Wullschleger, S.; Tichet, M.; Murugan, D.; Zangger, N.; Horton, W.; Korman, A.J.; Coussens, L.M.; Swartz, M.A.; Hanahan, D. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV(+) Cancers. Cancer Immunol. Res. 2020, 8, 131–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pfaendler, K.S.; Tewari, K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am. J. Obs. Gynecol 2016, 214, 22–30. [Google Scholar] [CrossRef] [Green Version]
- Bertotti, A.; Migliardi, G.; Galimi, F.; Sassi, F.; Torti, D.; Isella, C.; Corà, D.; Di Nicolantonio, F.; Buscarino, M.; Petti, C.; et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1, 508–523. [Google Scholar] [CrossRef] [Green Version]
- Sartore-Bianchi, A.; Trusolino, L.; Martino, C.; Bencardino, K.; Lonardi, S.; Bergamo, F.; Zagonel, V.; Leone, F.; Depetris, I.; Martinelli, E.; et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016, 17, 738–746. [Google Scholar] [CrossRef]
- Wilding, J.L.; Bodmer, W.F. Cancer cell lines for drug discovery and development. Cancer Res. 2014, 74, 2377–2384. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Qin, T.; Huang, Y.; Li, Y.; Chen, G.; Sun, C. Drug screening model meets cancer organoid technology. Transl. Oncol. 2020, 13, 100840. [Google Scholar] [CrossRef] [PubMed]
- Harrison, R.K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 2016, 15, 817–818. [Google Scholar] [CrossRef] [PubMed]
- Cho, S.Y.; Kang, W.; Han, J.Y.; Min, S.; Kang, J.; Lee, A.; Kwon, J.Y.; Lee, C.; Park, H. An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol. Cells 2016, 39, 77–86. [Google Scholar]
- Rosfjord, E.; Lucas, J.; Li, G.; Gerber, H.P. Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 2014, 91, 135–143. [Google Scholar] [CrossRef]
- Hidalgo, M.; Bruckheimer, E.; Rajeshkumar, N.V.; Garrido-Laguna, I.; De Oliveira, E.; Rubio-Viqueira, B.; Strawn, S.; Wick, M.J.; Martell, J.; Sidransky, D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10, 1311–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, C.; Lin, W.; Huang, Y.; Chen, X.; Wang, H.; Teng, L. The Essential Factors of Establishing Patient-derived Tumor Model. J. Cancer 2021, 12, 28–37. [Google Scholar] [CrossRef]
- Sajjad, H.; Imtiaz, S.; Noor, T.; Siddiqui, Y.H.; Sajjad, A.; Zia, M. Cancer models in preclinical research: A chronicle review of advancement in effective cancer research. Anim. Models Exp. Med. 2021, 4, 87–103. [Google Scholar] [CrossRef] [PubMed]
- Jin, K.T.; Du, W.L.; Lan, H.R.; Liu, Y.Y.; Mao, C.S.; Du, J.L.; Mou, X.Z. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review. Cancer Sci. 2021, 112, 2592–2606. [Google Scholar] [CrossRef] [PubMed]
- Moiola, C.P.; Lopez-Gil, C.; Cabrera, S.; Garcia, A.; Van Nyen, T.; Annibali, D.; Fonnes, T.; Vidal, A.; Villanueva, A.; Matias-Guiu, X.; et al. Patient-Derived Xenograft Models for Endometrial Cancer Research. Int. J. Mol. Sci. 2018, 19, 2431. [Google Scholar] [CrossRef] [Green Version]
- Durinikova, E.; Buzo, K.; Arena, S. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: Past and future challenges. J. Exp. Clin. Cancer Res. CR 2021, 40, 185. [Google Scholar] [CrossRef]
- Rizzo, G.; Bertotti, A.; Leto, S.M.; Vetrano, S. Patient-derived tumor models: A more suitable tool for pre-clinical studies in colorectal cancer. J. Exp. Clin. Cancer Res. CR 2021, 40, 178. [Google Scholar] [CrossRef] [PubMed]
- Gao, H.; Korn, J.M.; Ferretti, S.; Monahan, J.E.; Wang, Y.; Singh, M.; Zhang, C.; Schnell, C.; Yang, G.; Zhang, Y.; et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 2015, 21, 1318–1325. [Google Scholar] [CrossRef]
- Aytes, A.; Molleví, D.G.; Martinez-Iniesta, M.; Nadal, M.; Vidal, A.; Morales, A.; Salazar, R.; Capellà, G.; Villanueva, A. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol. Carcinog. 2012, 51, 746–753. [Google Scholar] [CrossRef]
- Choi, Y.Y.; Lee, J.E.; Kim, H.; Sim, M.H.; Kim, K.K.; Lee, G.; Kim, H.I.; An, J.Y.; Hyung, W.J.; Kim, C.B.; et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci. Rep. 2016, 6, 22172. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Claerhout, S.; Prat, A.; Dobrolecki, L.E.; Petrovic, I.; Lai, Q.; Landis, M.D.; Wiechmann, L.; Schiff, R.; Giuliano, M.; et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013, 73, 4885–4897. [Google Scholar] [CrossRef] [Green Version]
- Chen, Q.; Wei, T.; Wang, J.; Zhang, Q.; Li, J.; Zhang, J.; Ni, L.; Wang, Y.; Bai, X.; Liang, T. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Pancreatology 2020, 20, 485–492. [Google Scholar] [CrossRef]
- Mattie, M.; Christensen, A.; Chang, M.S.; Yeh, W.; Said, S.; Shostak, Y.; Capo, L.; Verlinsky, A.; An, Z.; Joseph, I.; et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 2013, 15, 1138–1150. [Google Scholar] [CrossRef]
- Lee, H.W.; Lee, J.I.; Lee, S.J.; Cho, H.J.; Song, H.J.; Jeong, D.E.; Seo, Y.J.; Shin, S.; Joung, J.G.; Kwon, Y.J.; et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin. Cancer Res. 2015, 21, 1172–1182. [Google Scholar] [CrossRef] [Green Version]
- Dong, X.; Guan, J.; English, J.C.; Flint, J.; Yee, J.; Evans, K.; Murray, N.; Macaulay, C.; Ng, R.T.; Gout, P.W.; et al. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 2010, 16, 1442–1451. [Google Scholar] [CrossRef] [Green Version]
- Zhu, M.; Li, L.; Lu, T.; Yoo, H.; Zhu, J.; Gopal, P.; Wang, S.C.; Porempka, M.R.; Rich, N.E.; Kagan, S.; et al. Uncovering biological factors that regulate hepatocellular carcinoma growth using patient derived xenograft assays. Hepatology 2020, 72, 1085–1101. [Google Scholar] [CrossRef]
- Sivanand, S.; Peña-Llopis, S.; Zhao, H.; Kucejova, B.; Spence, P.; Pavia-Jimenez, A.; Yamasaki, T.; McBride, D.J.; Gillen, J.; Wolff, N.C.; et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 2012, 4, 137ra75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, B.; Jeong, B.C.; Choi, Y.L.; Kwon, G.Y.; Lim, J.E.; Seo, S.I.; Jeon, S.S.; Lee, H.M.; Choi, H.Y.; Lee, K.S. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci. 2013, 104, 631–638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoffmann, C.; Bachran, C.; Stanke, J.; Elezkurtaj, S.; Kaufmann, A.M.; Fuchs, H.; Loddenkemper, C.; Schneider, A.; Cichon, G. Creation and characterization of a xenograft model for human cervical cancer. Gynecol. Oncol. 2010, 118, 76–80. [Google Scholar] [CrossRef] [PubMed]
- Chaudary, N.; Pintilie, M.; Schwock, J.; Dhani, N.; Clarke, B.; Milosevic, M.; Fyles, A.; Hill, R.P. Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers 2012, 4, 821–845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hiroshima, Y.; Zhang, Y.; Zhang, N.; Maawy, A.; Mii, S.; Yamamoto, M.; Uehara, F.; Miwa, S.; Yano, S.; Murakami, T.; et al. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS ONE 2015, 10, e0117417. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.S.; Yoon, G.; Ryu, J.Y.; Cho, Y.J.; Choi, J.J.; Lee, Y.Y.; Kim, T.J.; Choi, C.H.; Song, S.Y.; Kim, B.G.; et al. Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget 2015, 6, 26746–26756. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oh, D.Y.; Kim, S.; Choi, Y.L.; Cho, Y.J.; Oh, E.; Choi, J.J.; Jung, K.; Song, J.Y.; Ahn, S.E.; Kim, B.G.; et al. HER2 as a novel therapeutic target for cervical cancer. Oncotarget 2015, 6, 36219–36230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rofstad, E.K.; Simonsen, T.G.; Huang, R.; Andersen, L.M.; Galappathi, K.; Ellingsen, C.; Wegner, C.S.; Hauge, A.; Gaustad, J.V. Patient-derived xenograft models of squamous cell carcinoma of the uterine cervix. Cancer Lett. 2016, 373, 147–155. [Google Scholar] [CrossRef] [PubMed]
- Murakami, T.; Murata, T.; Kawaguchi, K.; Kiyuna, T.; Igarashi, K.; Hwang, H.K.; Hiroshima, Y.; Hozumi, C.; Komatsu, S.; Kikuchi, T.; et al. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel. Anticancer Res. 2017, 37, 61–65. [Google Scholar] [CrossRef] [Green Version]
- Larmour, L.I.; Cousins, F.L.; Teague, J.A.; Deane, J.A.; Jobling, T.W.; Gargett, C.E. A patient derived xenograft model of cervical cancer and cervical dysplasia. PLoS ONE 2018, 13, e0206539. [Google Scholar] [CrossRef]
- Yang, W.; Fan, W.S.; Ye, M.X.; Li, Z.; Gu, C.L.; Zhu, Y.P.; Hao, Y.P.; Wang, Z.Q.; Wang, L.; Meng, Y.G. Establishment of the PDTX model of gynecological tumors. Am. J. Transl. Res. 2019, 11, 3779–3789. [Google Scholar]
- Noh, J.J.; Kim, M.S.; Cho, Y.J.; Jeong, S.Y.; Lee, Y.Y.; Ryu, J.Y.; Choi, J.J.; Bae, I.; Wu, Z.; Kim, B.G.; et al. Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. Pharmaceutics 2020, 12, 987. [Google Scholar] [CrossRef]
- Zhu, M.; Jia, N.; Nie, Y.; Chen, J.; Jiang, Y.; Lv, T.; Li, Y.; Yao, L.; Feng, W. Establishment of Patient-Derived Tumor Xenograft Models of High-Risk Endometrial Cancer. Int. J. Gynecol. Cancer 2018, 28, 1812–1820. [Google Scholar] [CrossRef]
- Unno, K.; Ono, M.; Winder, A.D.; Maniar, K.P.; Paintal, A.S.; Yu, Y.; Wei, J.J.; Lurain, J.R.; Kim, J.J. Establishment of human patient-derived endometrial cancer xenografts in NOD scid gamma mice for the study of invasion and metastasis. PLoS ONE 2014, 9, e116064. [Google Scholar] [CrossRef]
- Depreeuw, J.; Hermans, E.; Schrauwen, S.; Annibali, D.; Coenegrachts, L.; Thomas, D.; Luyckx, M.; Gutierrez-Roelens, I.; Debruyne, D.; Konings, K.; et al. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol. Oncol. 2015, 139, 118–126. [Google Scholar] [CrossRef] [PubMed]
- Cabrera, S.; Llauradó, M.; Castellví, J.; Fernandez, Y.; Alameda, F.; Colás, E.; Ruiz, A.; Doll, A.; Schwartz, S., Jr.; Carreras, R.; et al. Generation and characterization of orthotopic murine models for endometrial cancer. Clin. Exp. Metastasis 2012, 29, 217–227. [Google Scholar] [CrossRef]
- Haldorsen, I.S.; Popa, M.; Fonnes, T.; Brekke, N.; Kopperud, R.; Visser, N.C.; Rygh, C.B.; Pavlin, T.; Salvesen, H.B.; McCormack, E.; et al. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS ONE 2015, 10, e0135220. [Google Scholar] [CrossRef] [Green Version]
- Wu, J.; Zheng, Y.; Tian, Q.; Yao, M.; Yi, X. Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis. J. Obstet. Gynaecol. Res. 2019, 45, 2062–2073. [Google Scholar] [CrossRef]
- Dobbin, Z.C.; Katre, A.A.; Steg, A.D.; Erickson, B.K.; Shah, M.M.; Alvarez, R.D.; Conner, M.G.; Schneider, D.; Chen, D.; Landen, C.N. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 2014, 5, 8750–8764. [Google Scholar] [CrossRef] [Green Version]
- Eoh, K.J.; Chung, Y.S.; Lee, S.H.; Park, S.A.; Kim, H.J.; Yang, W.; Lee, I.O.; Lee, J.Y.; Cho, H.; Chay, D.B.; et al. Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2018, 50, 956–963. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heo, E.J.; Cho, Y.J.; Cho, W.C.; Hong, J.E.; Jeon, H.K.; Oh, D.Y.; Choi, Y.L.; Song, S.Y.; Choi, J.J.; Bae, D.S.; et al. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2017, 49, 915–926. [Google Scholar] [CrossRef] [Green Version]
- Weroha, S.J.; Becker, M.A.; Enderica-Gonzalez, S.; Harrington, S.C.; Oberg, A.L.; Maurer, M.J.; Perkins, S.E.; AlHilli, M.; Butler, K.A.; McKinstry, S.; et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 2014, 20, 1288–1297. [Google Scholar] [CrossRef] [Green Version]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021, 88, 105906. [Google Scholar] [CrossRef] [PubMed]
- Collins, A.; Ross, J.; Lang, S.H. A systematic review of the asymmetric inheritance of cellular organelles in eukaryotes: A critique of basic science validity and imprecision. PLoS ONE 2017, 12, e0178645. [Google Scholar] [CrossRef] [PubMed]
- Guerrera, F.; Tabbò, F.; Bessone, L.; Maletta, F.; Gaudiano, M.; Ercole, E.; Annaratone, L.; Todaro, M.; Boita, M.; Filosso, P.L.; et al. The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. PLoS ONE 2016, 11, e0145100. [Google Scholar] [CrossRef]
- Drapkin, B.J.; George, J.; Christensen, C.L.; Mino-Kenudson, M.; Dries, R.; Sundaresan, T.; Phat, S.; Myers, D.T.; Zhong, J.; Igo, P.; et al. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018, 8, 600–615. [Google Scholar] [CrossRef] [Green Version]
- Flanagan, S.P. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet. Res. 1966, 8, 295–309. [Google Scholar] [CrossRef] [Green Version]
- Bosma, G.C.; Custer, R.P.; Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301, 527–530. [Google Scholar] [CrossRef]
- McCune, J.M.; Namikawa, R.; Kaneshima, H.; Shultz, L.D.; Lieberman, M.; Weissman, I.L. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988, 241, 1632–1639. [Google Scholar] [CrossRef]
- Mosier, D.E.; Gulizia, R.J.; Baird, S.M.; Wilson, D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988, 335, 256–259. [Google Scholar] [CrossRef] [PubMed]
- Thomsen, M.; Galvani, S.; Canivet, C.; Kamar, N.; Böhler, T. Reconstitution of immunodeficient SCID/beige mice with human cells: Applications in preclinical studies. Toxicology 2008, 246, 18–23. [Google Scholar] [CrossRef] [PubMed]
- Mosier, D.E.; Stell, K.L.; Gulizia, R.J.; Torbett, B.E.; Gilmore, G.L. Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J. Exp. Med. 1993, 177, 191–194. [Google Scholar] [CrossRef] [PubMed]
- Kikutani, H.; Makino, S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 1992, 51, 285–322. [Google Scholar] [PubMed]
- Gerling, I.C.; Serreze, D.V.; Christianson, S.W.; Leiter, E.H. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes 1992, 41, 1672–1676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ito, M.; Hiramatsu, H.; Kobayashi, K.; Suzue, K.; Kawahata, M.; Hioki, K.; Ueyama, Y.; Koyanagi, Y.; Sugamura, K.; Tsuji, K.; et al. NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood 2002, 100, 3175–3182. [Google Scholar] [CrossRef]
- Shultz, L.D.; Lyons, B.L.; Burzenski, L.M.; Gott, B.; Chen, X.; Chaleff, S.; Kotb, M.; Gillies, S.D.; King, M.; Mangada, J.; et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174, 6477–6489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morton, J.J.; Bird, G.; Refaeli, Y.; Jimeno, A. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res. 2016, 76, 6153–6158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, M.; Yao, L.C.; Cheng, M.; Cai, D.; Martinek, J.; Pan, C.X.; Shi, W.; Ma, A.H.; De Vere White, R.W.; Airhart, S.; et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2018, 32, 1537–1549. [Google Scholar] [CrossRef] [Green Version]
- Rongvaux, A.; Willinger, T.; Martinek, J.; Strowig, T.; Gearty, S.V.; Teichmann, L.L.; Saito, Y.; Marches, F.; Halene, S.; Palucka, A.K.; et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 2014, 32, 364–372. [Google Scholar] [CrossRef]
- Wunderlich, M.; Chou, F.S.; Link, K.A.; Mizukawa, B.; Perry, R.L.; Carroll, M.; Mulloy, J.C. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010, 24, 1785–1788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.; Kim, H.; Lee, J.E.; Shin, S.J.; Oh, S.; Kwon, G.; Kim, H.; Choi, Y.Y.; White, M.A.; Paik, S.; et al. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology 2018, 155, 799–814.e13. [Google Scholar] [CrossRef]
- Naito, S.; von Eschenbach, A.C.; Giavazzi, R.; Fidler, I.J. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986, 46, 4109–4115. [Google Scholar] [PubMed]
- Rubio-Viqueira, B.; Jimeno, A.; Cusatis, G.; Zhang, X.; Iacobuzio-Donahue, C.; Karikari, C.; Shi, C.; Danenberg, K.; Danenberg, P.V.; Kuramochi, H.; et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12, 4652–4661. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Revelo, M.P.; Sudilovsky, D.; Cao, M.; Chen, W.G.; Goetz, L.; Xue, H.; Sadar, M.; Shappell, S.B.; Cunha, G.R.; et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64, 149–159. [Google Scholar] [CrossRef]
- Jung, J.; Lee, C.H.; Seol, H.S.; Choi, Y.S.; Kim, E.; Lee, E.J.; Rhee, J.K.; Singh, S.R.; Jun, E.S.; Han, B.; et al. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget 2016, 7, 62533–62546. [Google Scholar] [CrossRef] [Green Version]
- Magnotti, E.; Marasco, W.A. The latest animal models of ovarian cancer for novel drug discovery. Expert Opin. Drug Discov. 2018, 13, 249–257. [Google Scholar] [CrossRef]
- Khanna, C.; Hunter, K. Modeling metastasis in vivo. Carcinogenesis 2005, 26, 513–523. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Zhang, R.; Wang, L.; Correa, A.M.; Pataer, A.; Xu, Y.; Zhang, X.; Ren, C.; Wu, S.; Meng, Q.H.; et al. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer 2019, 125, 3738–3748. [Google Scholar] [CrossRef]
- Oh, B.Y.; Lee, W.Y.; Jung, S.; Hong, H.K.; Nam, D.H.; Park, Y.A.; Huh, J.W.; Yun, S.H.; Kim, H.C.; Chun, H.K.; et al. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget 2015, 6, 16059–16068. [Google Scholar] [CrossRef] [Green Version]
- Hu, B.; Li, H.; Guo, W.; Sun, Y.F.; Zhang, X.; Tang, W.G.; Yang, L.X.; Xu, Y.; Tang, X.Y.; Ding, G.H.; et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int. J. Cancer 2020, 146, 1606–1617. [Google Scholar] [CrossRef]
- Jung, J.; Seol, H.S.; Chang, S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2018, 50, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Risbridger, G.P.; Toivanen, R.; Taylor, R.A. Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models. Cold Spring Harb. Perspect. Med. 2018, 8, a030536. [Google Scholar] [CrossRef] [Green Version]
- Hernandez, M.C.; Bergquist, J.R.; Leiting, J.L.; Ivanics, T.; Yang, L.; Smoot, R.L.; Nagorney, D.M.; Truty, M.J. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract 2019, 23, 818–824. [Google Scholar] [CrossRef] [PubMed]
- Oshi, M.; Okano, M.; Maiti, A.; Rashid, O.M.; Saito, K.; Kono, K.; Matsuyama, R.; Endo, I.; Takabe, K. Novel Breast Cancer Brain Metastasis Patient-Derived Orthotopic Xenograft Model for Preclinical Studies. Cancers 2020, 12, 444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Byrne, A.T.; Alférez, D.G.; Amant, F.; Annibali, D.; Arribas, J.; Biankin, A.V.; Bruna, A.; Budinská, E.; Caldas, C.; Chang, D.K.; et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 2017, 17, 254–268. [Google Scholar] [CrossRef] [PubMed]
- Nunes, M.; Vrignaud, P.; Vacher, S.; Richon, S.; Lièvre, A.; Cacheux, W.; Weiswald, L.B.; Massonnet, G.; Chateau-Joubert, S.; Nicolas, A.; et al. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Cancer Res. 2015, 75, 1560–1566. [Google Scholar] [CrossRef] [Green Version]
- Meric-Bernstam, F.; Hurwitz, H.; Raghav, K.P.S.; McWilliams, R.R.; Fakih, M.; VanderWalde, A.; Swanton, C.; Kurzrock, R.; Burris, H.; Sweeney, C.; et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019, 20, 518–530. [Google Scholar] [CrossRef]
- Tosi, F.; Sartore-Bianchi, A.; Lonardi, S.; Amatu, A.; Leone, F.; Ghezzi, S.; Martino, C.; Bencardino, K.; Bonazzina, E.; Bergamo, F.; et al. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. Clin. Colorectal Cancer 2020, 19, 256–262.e2. [Google Scholar] [CrossRef]
- Bertotti, A.; Papp, E.; Jones, S.; Adleff, V.; Anagnostou, V.; Lupo, B.; Sausen, M.; Phallen, J.; Hruban, C.A.; Tokheim, C.; et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015, 526, 263–267. [Google Scholar] [CrossRef]
- Bardelli, A.; Corso, S.; Bertotti, A.; Hobor, S.; Valtorta, E.; Siravegna, G.; Sartore-Bianchi, A.; Scala, E.; Cassingena, A.; Zecchin, D.; et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3, 658–673. [Google Scholar] [CrossRef] [Green Version]
- Kavuri, S.M.; Jain, N.; Galimi, F.; Cottino, F.; Leto, S.M.; Migliardi, G.; Searleman, A.C.; Shen, W.; Monsey, J.; Trusolino, L.; et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015, 5, 832–841. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schütte, M.; Risch, T.; Abdavi-Azar, N.; Boehnke, K.; Schumacher, D.; Keil, M.; Yildiriman, R.; Jandrasits, C.; Borodina, T.; Amstislavskiy, V.; et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 2017, 8, 14262. [Google Scholar] [CrossRef] [Green Version]
- Hinze, L.; Labrosse, R.; Degar, J.; Han, T.; Schatoff, E.M.; Schreek, S.; Karim, S.; McGuckin, C.; Sacher, J.R.; Wagner, F.; et al. Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discov. 2020, 10, 1690–1705. [Google Scholar] [CrossRef] [PubMed]
- Hidalgo, M.; Amant, F.; Biankin, A.V.; Budinská, E.; Byrne, A.T.; Caldas, C.; Clarke, R.B.; de Jong, S.; Jonkers, J.; Mælandsmo, G.M.; et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014, 4, 998–1013. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moser, J.; van Ark, J.; van Dijk, M.C.; Greiner, D.L.; Shultz, L.D.; van Goor, H.; Hillebrands, J.L. Distinct Differences on Neointima Formation in Immunodeficient and Humanized Mice after Carotid or Femoral Arterial Injury. Sci. Rep. 2016, 6, 35387. [Google Scholar] [CrossRef] [Green Version]
- Naserian, S.; Leclerc, M.; Thiolat, A.; Pilon, C.; Le Bret, C.; Belkacemi, Y.; Maury, S.; Charlotte, F.; Cohen, J.L. Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. Front. Immunol. 2018, 9, 10. [Google Scholar] [CrossRef] [Green Version]
- Sanmamed, M.F.; Rodriguez, I.; Schalper, K.A.; Oñate, C.; Azpilikueta, A.; Rodriguez-Ruiz, M.E.; Morales-Kastresana, A.; Labiano, S.; Pérez-Gracia, J.L.; Martín-Algarra, S.; et al. Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. Cancer Res. 2015, 75, 3466–3478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De La Rochere, P.; Guil-Luna, S.; Decaudin, D.; Azar, G.; Sidhu, S.S.; Piaggio, E. Humanized Mice for the Study of Immuno-Oncology. Trends Immunol. 2018, 39, 748–763. [Google Scholar] [CrossRef] [PubMed]
- Yoshihara, S.; Li, Y.; Xia, J.; Danzl, N.; Sykes, M.; Yang, Y.G. Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice. Front. Immunol. 2019, 10, 186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, D.J.; Lin, L.J.; Moon, H.; Pham, A.T.; Wang, X.; Liu, S.; Ji, S.; Rezek, V.; Shimizu, S.; Ruiz, M.; et al. Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. Stem Cells Dev. 2016, 25, 1863–1873. [Google Scholar] [CrossRef] [Green Version]
- Tang, Y.; Yang, Y.G.; Bai, O.; Xia, J.; Hu, Z. Long-term survival and differentiation of human thymocytes in human thymus-grafted immunodeficient mice. Immunotherapy 2019, 11, 881–888. [Google Scholar] [CrossRef]
Author, Year | Country | Animal Model | Histology | Type of Procedure for Obtaining the Tumor | Time between Surgery and Implantation |
---|---|---|---|---|---|
Hoffmann et al., 2010 [28] | Germany | SCID | Sq, Ad, Ne | NI | 2–5 h |
Chaudary et al., 2012 [29] | Canada | SCID, NOD SCID | Sq, Ad, C, M | Biopsy | Immediately |
Hiroshima et al., 2015 [30] | Japan | Nude | NI | Surgery | NI |
Kim et al., 2015 [31] | Korea | Nude | NI | Surgery | NI |
Oh et al., 2015 [32] | Korea | Nude | Sq, Ad | Surgery | NI |
Rofstad et al., 2016 [33] | Norway | Nude | Sq | Biopsy | NI |
Murakami et al., 2017 [34] | Japan | Nude | Sq | Surgery | Immediately |
Larmour et al., 2018 [35] | Australia | NSG | Sq, Ad | Biopsy | <8 h |
Yang et al., 2019 [36] | China | NCG | Sq | Biopsy | <12 h |
Noh et al., 2020 [37] | Korea | Nude | Sq, Ad | Surgery | NI |
Author, Year | Fragment Size | Site of Transplantation | Method of Graft | Mean Latency | Number of Donor Patient | Engraftment Rate (%) | Aim of the Study |
---|---|---|---|---|---|---|---|
Hoffmann et al., 2010 [28] | 3–5 mm | Subcutaneous | Direct | 6 | 0 (0/6) | Evaluate the PDX method | |
Minced | Injection | 6–8 weeks | 10 | 70 (7/10) | |||
Chaudary et al., 2012 [29] | 1–2 mm | Cervix | Direct | 3–4 months | 33 | 48 (16/33) | Evaluate the PDX method |
Hiroshima et al., 2015 [30] | 3 mm3 | Subcutaneous | Direct | 10–15 days | 1 | 70 (7/10) | Evaluate the PDX method |
3 mm3 | Cervix | Direct | 10–15 days | 75 (6/8) | |||
Kim et al., 2015 [31] | 2–3 mm | Subrenal capsule | Direct | NI | 1 | NI | Drug evaluation |
Oh et al., 2015 [32] | 1 mm3 | Subrenal capsule | Direct | 2–12 months | 21 | 66.7 (14/21) | Drug evaluation |
Rofstad et al., 2016 [33] | 1 mm | Subcutaneous | Direct | NI | 4 | NI | Evaluate the PDX method |
Murakami et al., 2017 [31] | 5 mm | Subcutaneous | Direct | 4 weeks | 1 | NI | Drug evaluation |
Larmour et al., 2018 [35] | 1 mm3 | Subrenal capsule | Direct | 227 days | 14 | 71.4 (10/14) | Evaluate the PDX method |
Yang et al., 2019 [36] | 8 mm3 | Subcutaneous | Injection | 73 (21–130) days | 2 | NI | Drug evaluation |
Noh et al., 2020 [37] | 2–3 mm | Subrenal capsule | Direct | NI | 5 | NI | Drug evaluation |
Author, Year of Publication | Driver Gene Mutation | Gene Expression | Copy Number Variation | Proteomics | Immunohistochemistry |
---|---|---|---|---|---|
Hoffmann et al., 2010 [28] | No | No | No | No | EGFR, MHC, p16, ki-67, HPV18E7 |
Chaudary et al., 2012 [29] | No | No | No | No | CA9, CD31, Ki67, LYVE, EF5, SMA, collagen IV, cytokeratin |
Hiroshima et al., 2015 [30] | No | No | No | No | HER-2 |
Oh et al., 2015 [32] | No | Yes | Yes | No | HER-2 |
Murakami et al., 2017 [34] | No | No | No | No | No |
Larmour et al., 2018 [35]. | No | No | No | No | P16, HuNu, HPV, CD45 |
Yang et al., 2019 [36] | No | No | No | No | No |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tanaka, T.; Nishie, R.; Ueda, S.; Miyamoto, S.; Hashida, S.; Konishi, H.; Terada, S.; Kogata, Y.; Sasaki, H.; Tsunetoh, S.; et al. Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review. Int. J. Mol. Sci. 2021, 22, 9369. https://doi.org/10.3390/ijms22179369
Tanaka T, Nishie R, Ueda S, Miyamoto S, Hashida S, Konishi H, Terada S, Kogata Y, Sasaki H, Tsunetoh S, et al. Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review. International Journal of Molecular Sciences. 2021; 22(17):9369. https://doi.org/10.3390/ijms22179369
Chicago/Turabian StyleTanaka, Tomohito, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, and et al. 2021. "Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review" International Journal of Molecular Sciences 22, no. 17: 9369. https://doi.org/10.3390/ijms22179369